The artificial intelligence (AI)-enabled VisiRad XR reportedly demonstrated an 83 percent sensitivity rate for detecting lung nodules and masses on chest X-rays in one retrospective study.
VisiRad XR, which utilizes artificial intelligence (AI) to facilitate diagnosis of suspicious lung masses and nodules on chest X-rays, has garnered 510(k) clearance from the Food and Drug Administration (FDA).
Noting that subtle lung nodules are often overlooked on chest X-rays, IMIDEX, the manufacturer of VisiRad XR, says the software routes images with AI-detected nodules back to radiologists without the need for additional testing orders.
In a retrospective study examining the use of VisiRad XR on over 11,000 patient images, the AI software reportedly had an 83 percent sensitivity rate for identifying lung masses and nodules, according to IMIDEX. The company suggests that VisiRad XR could facilitate the additional diagnosis of 750 lung nodules or masses a year at hospitals performing 50,000 chest X-rays annually.
“Currently, only 20% of lung cancers are detected in the early stages and only 4% of patients at high risk for lung cancer are routinely screened,” noted Paul Bunn, M.D., a professor of medical oncology at the University of Colorado and former president of the American Society of Clinical Oncology (ASCO). “Increasing our detection of existing lung nodules is key to identifying it early when the patient’s likelihood of survival is markedly higher.”
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Can CT-Based Deep Learning Bolster Prognostic Assessments of Ground-Glass Nodules?
June 19th 2025Emerging research shows that a multiple time-series deep learning model assessment of CT images provides 20 percent higher sensitivity than a delta radiomic model and 56 percent higher sensitivity than a clinical model for prognostic evaluation of ground-glass nodules.